Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1002/lio2.532 http://scihub22266oqcxt.onion/10.1002/lio2.532 33821217!8014200!33821217     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=33821217&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       Laryngoscope+Investig+Otolaryngol 2021 ; 6 (2): 172-176 Nephropedia Template TP {{tp|p=33821217|t=2021. Short-term chemosensory distortions and phantoms in COVID-19 |pdf=|usr=}}{{33821217}} gab.com Text Short-term chemosensory distortions and phantoms in COVID-19 JO: Laryngoscope Investig Otolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=33821217 #FOAvip OBJECTIVE: To identify differentiation features of chemosensory dysfunction in COVID-19 infection and their primary drivers. STUDY DESIGN: Cross-sectional cohort comparison. METHODS: A national anonymous survey was used to query participants regarding nasal symptoms and chemosensory dysfunction including sensitivity levels, and presence or absence of distortions and phantoms within the 6-week time window surrounding their COVID-19 testing and survey completion. RESULTS: Three-hundred and sixty-four respondents who reported COVID-19 positive (COVID+; n = 176) or COVID-19 negative (COVID-; n = 188) test results completed the survey. The COVID+ cohort had higher occurrence rates for: (a) chemosensory sensitivity impairments (67.0% vs 30.3%; P < .01), where the rate of complete loss of smell (anosmia) or taste (ageusia) was higher (35.8% vs 4.8%; P < .01), and (b) chemosensory distortions (39.8% vs 19.1%; P < .01), where the rate of anosmia or ageusia with distortions was also higher in the COVID+ cohort (19.9% vs 2.7%; P < .01). Occurrence rates in the two cohorts were similar for chemosensory phantoms (COVID+ 17.0%, COVID- 18.6%; P = .70) and nasal discharge or stuffiness in the presence of sensitivity impairment (COVID+ 63.6%, COVID- 52.6%; P = .17). CONCLUSION: Chemosensory dysfunction in COVID-19 is associated with higher rates of smell or taste sensitivity impairments and distortions. Higher rates of anosmia and ageusia drive these key findings. Chemosensory phantoms and nasal symptoms in the presence of sensitivity impairment occur at rates that should demand clinical attention, but they do not appear to be specific to COVID-19 positivity. LEVEL OF EVIDENCE: 2b. Twit Text FOAVip Short-term chemosensory distortions and phantoms in COVID-19 ????Laryngoscope Investig Otolaryngol http://www.kidney.de/pget.php?&tw=1&pmid=33821217 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33821217 #FOAvip English Wikipedia <ref>{{Cite pmid|33821217}}</ref> Short-term chemosensory distortions and phantoms in COVID-19 #MMPMID33821217 Gurrola JG 2nd; Chang JL; Roland LT; Loftus PA; Cheung SW Laryngoscope Investig Otolaryngol 2021[Apr]; 6 (2): 172-176 PMID33821217show ga OBJECTIVE: To identify differentiation features of chemosensory dysfunction in COVID-19 infection and their primary drivers. STUDY DESIGN: Cross-sectional cohort comparison. METHODS: A national anonymous survey was used to query participants regarding nasal symptoms and chemosensory dysfunction including sensitivity levels, and presence or absence of distortions and phantoms within the 6-week time window surrounding their COVID-19 testing and survey completion. RESULTS: Three-hundred and sixty-four respondents who reported COVID-19 positive (COVID+; n = 176) or COVID-19 negative (COVID-; n = 188) test results completed the survey. The COVID+ cohort had higher occurrence rates for: (a) chemosensory sensitivity impairments (67.0% vs 30.3%; P < .01), where the rate of complete loss of smell (anosmia) or taste (ageusia) was higher (35.8% vs 4.8%; P < .01), and (b) chemosensory distortions (39.8% vs 19.1%; P < .01), where the rate of anosmia or ageusia with distortions was also higher in the COVID+ cohort (19.9% vs 2.7%; P < .01). Occurrence rates in the two cohorts were similar for chemosensory phantoms (COVID+ 17.0%, COVID- 18.6%; P = .70) and nasal discharge or stuffiness in the presence of sensitivity impairment (COVID+ 63.6%, COVID- 52.6%; P = .17). CONCLUSION: Chemosensory dysfunction in COVID-19 is associated with higher rates of smell or taste sensitivity impairments and distortions. Higher rates of anosmia and ageusia drive these key findings. Chemosensory phantoms and nasal symptoms in the presence of sensitivity impairment occur at rates that should demand clinical attention, but they do not appear to be specific to COVID-19 positivity. LEVEL OF EVIDENCE: 2b. ?Short-term chemosensory distortions and phantoms in COVID-19 (epmc).pdf DeepDyve Pubget Overpricing